Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GNI Group ( (JP:2160) ) has provided an update.
GNI Group Ltd. announced that its subsidiary, Gyre Therapeutics, Inc., has presented a timeline for the New Drug Application submission for Hydronidone (F351) in the PRC, expected in the second quarter of 2025. The company plans to receive topline data from the Phase 3 clinical trial during this period, with further data analysis and NDA filing to follow, maintaining their previously stated timeline.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on the development of anti-fibrotic therapeutics for chronic organ diseases through its core subsidiary, Gyre Therapeutics, Inc.
YTD Price Performance: -35.85%
Average Trading Volume: 1,396
Technical Sentiment Signal: Buy
Current Market Cap: €706.3M
See more insights into 2160 stock on TipRanks’ Stock Analysis page.